EXLIBRIS

Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects. [ Time Frame: At 3 months from the inclusion ].

Experimental : EXL01 (1 capsule / day) + Nivolumab

1. Patients (male or female) ≥18 years old.
2. ECOG Performance status (PS) 0-1 (WHO).
3. Histologically or cytologically documented inoperable advanced/metastatic NSCLC. (inoperable stage III not amenable to radiation therapy or surgery, stage IV)
4. No alterations of key driver oncogenes including EGFR (mutations), ALK (fusions), ROS1 (fusions), MET (METex14 mutations), HER2 (exon 20 insertions), RET (fusions), or BRAF (V600E mutations). KRAS mutations are allowed.
5. Must have previously received anti-PD(L)1 agent and platinum-based chemotherapy, either concomitantly or sequentially. Last dose to have been administered more than 15 days prior to first dose of study drug.
6. Must have progressed within 6 months after first dose of anti-PD(L)1 given either alone or in combination with platinum-based chemotherapy.
7. Must have received all validated available standard therapies.
8. Measurable disease according to iRECIST 1.1.
9. Adequate hematological, renal and liver functions within 72 hours before the first dose of study treatment:
   • Absolute Neutrophil Count ≥ 1500/μL
   • Platelets ≥ 100 000/μL
   • Hemoglobin ≥ 9.0 g/dL
   • Creatinine Clearance ≥ 50 mL/min
   • Total Bilirubin ≤ 1.5 x ULN
   • AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN for participants with liver metastasis)

1. Small cell lung cancer or tumors with mixed histology including a SCLC component.
2. Known symptomatic CNS metastases and/or carcinomatous meningitis. Participants with asymptomatic brain metastases (ie, no neurological symptoms and no requirements for corticosteroids > 10mg/d prednisone equivalent) may participate.
3. Diagnosis of immunodeficiency of is receiving systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.
4. Living attenuated vaccine received within the 30 previous days.
5. Has received Fecal Microbiota Transplantation within 3 months prior to Screening.
6. General serious condition such as uncontrolled congestive cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction within the previous 6 months), history or stroke within the 6 previous months.
7. History of severe immune-mediated toxicity (≥ grade 3) under immunotherapy treatment.
8. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Lancement de l’étude : Février 2024
Fin estimée des inclusions : Juillet 2026
Nombre de patients à inclure : 600

Pr Alexis CORTOT – CHU Lille

CHU Lille